Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Latest Press Releases
Evaluate Vantage 2021 Preview: High hopes and valuations set the tone for biopharma
COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall the sector will start the year from a position of strength, according…
Evaluate Ltd. launches Evaluate Omnium, transforming pharma’s approach to quantifying the risk and return of novel drugs
Game-changing offering leverages the power of machine learning to fill critical information gaps in the early-stage pharmaceutical pipeline.
Evaluate Ltd. secures additional investment from Hg to drive further growth and expansion
Evaluate Ltd., a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, today announces that it has secured additional…
Browse the archive
Worldwide Orphan Drug Sales Are Forecast To Grow At A Cagr Of 11.3% From 2018 To 2024, Double The Rate Forecast For The Non-Orphan Drug Market
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
Fast Pace Of Drug And Device Approvals In 2017 Signals Wider Sector Health For Biopharma But Medtech Companies Struggle
EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.
Uptick In M&A Activity And Investor Cash Expected To Re-Invigorate Pharma And Biotech In 2018
EP Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2018.
Worldwide Medtech Sales Forecast To Reach $522 Billion By 2022 With A Cagr Of 5.1% Between 2016 And 2022
EvaluateMedTech Report Launches in Conjunction with The MedTech Conference.
Biopharma Stages A Strong Recovery Over The First Half Even As M&A Deals Disappoint, While Unprecedented Amounts Of Money Flow In Medtech But Not Towards Smaller Innovators
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Japanese Pharmaceutical Market Set To Grow 3.3% (Cagr) Between 2017 And 2022, Significantly Lower Than The Worldwide Outlook (6.5% Cagr)
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer
Pricing Pressure Causes Worldwide Drug Sales Forecasts To Fall For First Time In 10 Years
Fall comes as average cost of developing new drugs totals $4bn over the last 10 years.
Worldwide Prescription Drug Sales to Top Trillion Dollar Mark in 2022 with 32% of the 2022 Increase in Sales to Come From Orphan Drugs
Annual Pharma & Biotech World Preview Report to Launch at Bio 2017
